About the Study

The CanTalk Study is funded by the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) Programme with sites set up across England.

It is hosted by University College London, and is run from the Division of Psychiatry.

Why Depression and Why Cancer?

Depression is a common problem in people with cancer, which negatively impacts the well-being and quality of life for both them and their family. Research has shown there are benefits of using a talking therapy to treat depression in people who have cancer.

Cognitive Behavioural Therapy (CBT) is one such talking therapy. It has been shown to be most effective in changing negative thinking and unhelpful behaviours. However it is not yet fully known if this benefits people who have advanced cancer.

This where the CanTalk Study comes in.

The CanTalk Study is a Randomised Controlled Trial (RCT) looking to investigate the effectiveness of a 12-week course of CBT and treatment as usual to treat depression in people who have advanced cancer.

Each participant who enters the study is randomly assigned to one of two groups:

  • Treatment As Usual (this means usual care from a healthcare provider such as chemotherapy)
  • OR Treatment As Usual with the addition of CBT.

If you, or someone you know, are interested in taking part in the CanTalk Study, please read more in the 'Participants' link on this website.

Alternatively you are very welcome to contact the CanTalk Study team via email at: cantalk@ucl.ac.uk